NCT03516890 is a clinical trial of Partial hepatectomy in Rupture, Spontaneous, sponsored by Huazhong University of Science and Technology.

Who is sponsoring NCT03516890?

NCT03516890 is sponsored by Huazhong University of Science and Technology.

What drugs are being tested in NCT03516890?

Interventions in NCT03516890: Partial hepatectomy.

What condition does NCT03516890 study?

NCT03516890 studies Rupture, Spontaneous, Rupture Liver, Hepatocellular Carcinoma.

Is NCT03516890 still recruiting?

NCT03516890 is currently completed. Last updated 4 May 2018.

Last reviewed 2018-05-04 · How we verify

NCT03516890

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Management of Spontaneous Ruptured Hepatocellular Carcinoma

Completed Last updated 4 May 2018

What this trial tests

trial testing Partial hepatectomy in Rupture, Spontaneous in 216 participants. Completed in 1 December 2017.

Timeline

1 January 2005

Primary endpoint
1 June 2015

1 December 2017

Quick facts

Lead sponsor	Huazhong University of Science and Technology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	216
Start date	1 January 2005
Primary completion	1 June 2015
Estimated completion	1 December 2017

Drugs / interventions tested

Partial hepatectomy

Conditions studied

Rupture, Spontaneous — all drugs for Rupture, Spontaneous →
Rupture Liver — all drugs for Rupture Liver →
Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Huazhong University of Science and Technology

Who can join

Adults 15 to 76, any sex, with Rupture, Spontaneous or Rupture Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the best treatment for hepatocellular carcinoma rupture

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Partial hepatectomy

Trials testing the same drug.

NCT06954116 — Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence · Phase 2 · not yet recruiting

Other Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03516890 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
Last refreshed: 4 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03516890.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing